The mortality of COVID-19 in CML patients from 2020 until 2022: results from the EPICOVIDEHA survey
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023736%3A_____%2F24%3A00013585" target="_blank" >RIV/00023736:_____/24:00013585 - isvavai.cz</a>
Alternative codes found
RIV/00216224:14110/24:00135451 RIV/65269705:_____/24:00078546 RIV/00179906:_____/24:10481286 RIV/00098892:_____/24:10158181
Result on the web
<a href="https://doi.org/10.1080/10428194.2023.2280886" target="_blank" >https://doi.org/10.1080/10428194.2023.2280886</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1080/10428194.2023.2280886" target="_blank" >10.1080/10428194.2023.2280886</a>
Alternative languages
Result language
angličtina
Original language name
The mortality of COVID-19 in CML patients from 2020 until 2022: results from the EPICOVIDEHA survey
Original language description
Since the beginning of the COVID-19 pandemic, there has been an overall improvement in patient mortality. However, haematological malignancy patients continue to experience significant impacts from COVID-19, including high rates of hospitalization, intensive care unit (ICU) admissions, and mortality. In comparison to other haematological malignancy patients, individuals with chronic myeloid leukemia (CML) generally have better prognosis. This study, conducted using a large haematological malignancy patient database (EPICOVIDEHA), demonstrated that the majority of CML patients experienced mild infections. The decline in severe and critical infections over the years can largely be attributed to the widespread administration of vaccinations and the positive response they elicited. Notably, the mortality rate among CML patients was low and exhibited a downward trend in subsequent years. Importantly, our analysis provided confirmation of the effectiveness of vaccinations in CML patients.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30205 - Hematology
Result continuities
Project
—
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Others
Publication year
2024
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Leukemia & lymphoma
ISSN
1042-8194
e-ISSN
—
Volume of the periodical
65
Issue of the periodical within the volume
2
Country of publishing house
GB - UNITED KINGDOM
Number of pages
10
Pages from-to
199-208
UT code for WoS article
001103157000001
EID of the result in the Scopus database
2-s2.0-85176920648